Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Exact Sciences price target lowered to $81 from $100 at Craig-Hallum » 08:33
04/27/22
04/27
08:33
04/27/22
08:33
EXAS

Exact Sciences

$58.68 /

-3.925 (-6.27%)

Craig-Hallum analyst Alex…

Craig-Hallum analyst Alex Nowak lowered the firm's price target on Exact Sciences to $81 from $100 due to depressed multiples across genomics and potential capital needs. The analyst keeps a Buy rating on the shares following quarterly results.

ShowHide Related Items >><<
EXAS Exact Sciences
$58.68 /

-3.925 (-6.27%)

EXAS Exact Sciences
$58.68 /

-3.925 (-6.27%)

04/27/22 Baird
Exact Sciences price target lowered to $90 from $100 at Baird
04/27/22 Raymond James
Exact Sciences price target lowered to $80 from $90 at Raymond James
04/27/22 Citi
Exact Sciences price target lowered to $65 from $80 at Citi
02/23/22 Craig-Hallum
Exact Sciences price target lowered to $100 from $133 at Craig-Hallum
EXAS Exact Sciences
$58.68 /

-3.925 (-6.27%)

EXAS Exact Sciences
$58.68 /

-3.925 (-6.27%)

Recommendations
Exact Sciences price target lowered to $90 from $100 at Baird » 06:45
04/27/22
04/27
06:45
04/27/22
06:45
EXAS

Exact Sciences

$58.68 /

-3.925 (-6.27%)

Baird analyst Catherine…

Baird analyst Catherine Ramsay Schulte lowered the firm's price target on Exact Sciences to $90 from $100 and keeps an Outperform rating on the shares. The analyst said an anticipated upcoming competitive data readout remains an overhang for the stock near term, but she continues to think the core is well-positioned and that advances in the multi-cancer program could drive shares meaningfully higher over the next 12 months.

ShowHide Related Items >><<
EXAS Exact Sciences
$58.68 /

-3.925 (-6.27%)

EXAS Exact Sciences
$58.68 /

-3.925 (-6.27%)

04/27/22 Raymond James
Exact Sciences price target lowered to $80 from $90 at Raymond James
04/27/22 Citi
Exact Sciences price target lowered to $65 from $80 at Citi
02/23/22 Craig-Hallum
Exact Sciences price target lowered to $100 from $133 at Craig-Hallum
02/23/22 Raymond James
Exact Sciences price target lowered to $90 from $130 at Raymond James
EXAS Exact Sciences
$58.68 /

-3.925 (-6.27%)

EXAS Exact Sciences
$58.68 /

-3.925 (-6.27%)

Recommendations
Exact Sciences price target lowered to $80 from $90 at Raymond James » 06:44
04/27/22
04/27
06:44
04/27/22
06:44
EXAS

Exact Sciences

$58.68 /

-3.925 (-6.27%)

Raymond James analyst…

Raymond James analyst Andrew Cooper lowered the firm's price target on Exact Sciences to $80 from $90 and keeps an Outperform rating on the shares. After "noise" in the core Cologuard revenue base in recent periods, the ~6% beat in the segment should be well-received, Cooper tells investors in a research note. The analyst believes Exact is positioned for ongoing growth in Cologuard, with the channel strength to add products in both the primary care and oncology channels and a pipeline that should excite in both areas.

ShowHide Related Items >><<
EXAS Exact Sciences
$58.68 /

-3.925 (-6.27%)

EXAS Exact Sciences
$58.68 /

-3.925 (-6.27%)

04/27/22 Citi
Exact Sciences price target lowered to $65 from $80 at Citi
02/23/22 Craig-Hallum
Exact Sciences price target lowered to $100 from $133 at Craig-Hallum
02/23/22 Raymond James
Exact Sciences price target lowered to $90 from $130 at Raymond James
02/23/22 Wells Fargo
Exact Sciences price target lowered to $80 from $95 at Wells Fargo
EXAS Exact Sciences
$58.68 /

-3.925 (-6.27%)

EXAS Exact Sciences
$58.68 /

-3.925 (-6.27%)

Recommendations
Exact Sciences price target lowered to $65 from $80 at Citi » 06:22
04/27/22
04/27
06:22
04/27/22
06:22
EXAS

Exact Sciences

$58.68 /

-3.925 (-6.27%)

Citi analyst Patrick…

Citi analyst Patrick Donnelly lowered the firm's price target on Exact Sciences to $65 from $80 and keeps a Neutral rating on the shares following the Q1 results. The target drop reflects high-growth peer group multiple contraction in the current rising rate environment, Donnelly tells investors in a research note.

ShowHide Related Items >><<
EXAS Exact Sciences
$58.68 /

-3.925 (-6.27%)

EXAS Exact Sciences
$58.68 /

-3.925 (-6.27%)

02/23/22 Craig-Hallum
Exact Sciences price target lowered to $100 from $133 at Craig-Hallum
02/23/22 Raymond James
Exact Sciences price target lowered to $90 from $130 at Raymond James
02/23/22 Wells Fargo
Exact Sciences price target lowered to $80 from $95 at Wells Fargo
02/23/22 Baird
Exact Sciences price target lowered to $100 from $116 at Baird
EXAS Exact Sciences
$58.68 /

-3.925 (-6.27%)

EXAS Exact Sciences
$58.68 /

-3.925 (-6.27%)

Earnings
Exact Sciences raises FY22 revenue view to $1.985-$2.032 from $1.975B-$2.027B » 16:09
04/26/22
04/26
16:09
04/26/22
16:09
EXAS

Exact Sciences

$58.82 /

-3.78 (-6.04%)

Sees FY22 Screening…

Sees FY22 Screening revenue of $1.350B-$1.372B, including $40M-$42M from PreventionGenetics, Precision Oncology revenue of $595M-$610M, and COVID-19 testing revenue of $40M-$50M.

ShowHide Related Items >><<
EXAS Exact Sciences
$58.82 /

-3.78 (-6.04%)

EXAS Exact Sciences
$58.82 /

-3.78 (-6.04%)

02/23/22 Craig-Hallum
Exact Sciences price target lowered to $100 from $133 at Craig-Hallum
02/23/22 Raymond James
Exact Sciences price target lowered to $90 from $130 at Raymond James
02/23/22 Wells Fargo
Exact Sciences price target lowered to $80 from $95 at Wells Fargo
02/23/22 Baird
Exact Sciences price target lowered to $100 from $116 at Baird
EXAS Exact Sciences
$58.82 /

-3.78 (-6.04%)

EXAS Exact Sciences
$58.82 /

-3.78 (-6.04%)

Earnings
Exact Sciences reports Q1 EPS ($1.04), consensus ($1.07) » 16:07
04/26/22
04/26
16:07
04/26/22
16:07
EXAS

Exact Sciences

$58.95 /

-3.65 (-5.83%)

Reports Q1 revenue $487,…

Reports Q1 revenue $487, consensus $461.71M. Cash, cash equivalents, and marketable securities were $817.0M at the end of the quarter. "The Exact Sciences team delivered outstanding results to start 2022, testing a record number of people with Cologuard and Oncotype DX," said Kevin Conroy, chairman and CEO. "We plan to fundamentally change the way cancer is diagnosed and treated, powered by our strong foundation in cancer screening and precision oncology, our deep pipeline of innovative tests, and a clear path to sustainable, profitable growth."

ShowHide Related Items >><<
EXAS Exact Sciences
$58.95 /

-3.65 (-5.83%)

EXAS Exact Sciences
$58.95 /

-3.65 (-5.83%)

02/23/22 Craig-Hallum
Exact Sciences price target lowered to $100 from $133 at Craig-Hallum
02/23/22 Raymond James
Exact Sciences price target lowered to $90 from $130 at Raymond James
02/23/22 Wells Fargo
Exact Sciences price target lowered to $80 from $95 at Wells Fargo
02/23/22 Baird
Exact Sciences price target lowered to $100 from $116 at Baird
EXAS Exact Sciences
$58.95 /

-3.65 (-5.83%)

EXAS Exact Sciences
$58.95 /

-3.65 (-5.83%)

Over a month ago
Recommendations
Exact Sciences price target lowered to $100 from $133 at Craig-Hallum » 08:35
02/23/22
02/23
08:35
02/23/22
08:35
EXAS

Exact Sciences

$73.59 /

-0.58 (-0.78%)

Craig-Hallum analyst Alex…

Craig-Hallum analyst Alex Nowak lowered the firm's price target on Exact Sciences to $100 from $133 and keeps a Buy rating on the shares following quarterly results. The analyst notes that To the naked eye, it was a beat across business segments for Exact Sciences. But after looking through the print, Cologuard growth painted a much less exciting 2022, he contends.

ShowHide Related Items >><<
EXAS Exact Sciences
$73.59 /

-0.58 (-0.78%)

EXAS Exact Sciences
$73.59 /

-0.58 (-0.78%)

02/23/22 Raymond James
Exact Sciences price target lowered to $90 from $130 at Raymond James
02/23/22 Wells Fargo
Exact Sciences price target lowered to $80 from $95 at Wells Fargo
02/23/22 Baird
Exact Sciences price target lowered to $100 from $116 at Baird
02/23/22 Citi
Exact Sciences price target lowered to $80 from $100 at Citi
EXAS Exact Sciences
$73.59 /

-0.58 (-0.78%)

EXAS Exact Sciences
$73.59 /

-0.58 (-0.78%)

Recommendations
Exact Sciences price target lowered to $90 from $130 at Raymond James » 07:21
02/23/22
02/23
07:21
02/23/22
07:21
EXAS

Exact Sciences

$73.59 /

-0.58 (-0.78%)

Raymond James analyst…

Raymond James analyst Andrew Cooper lowered the firm's price target on Exact Sciences to $90 from $130 and keeps an Outperform rating on the shares. The Q4 results were relatively positive, but initial 2022 guidance appears to be a bit mixed, Cooper tells investors in a research note.

ShowHide Related Items >><<
EXAS Exact Sciences
$73.59 /

-0.58 (-0.78%)

EXAS Exact Sciences
$73.59 /

-0.58 (-0.78%)

02/23/22 Wells Fargo
Exact Sciences price target lowered to $80 from $95 at Wells Fargo
02/23/22 Baird
Exact Sciences price target lowered to $100 from $116 at Baird
02/23/22 Citi
Exact Sciences price target lowered to $80 from $100 at Citi
11/03/21 BTIG
Exact Sciences price target lowered to $120 from $145 at BTIG
EXAS Exact Sciences
$73.59 /

-0.58 (-0.78%)

EXAS Exact Sciences
$73.59 /

-0.58 (-0.78%)

Recommendations
Exact Sciences price target lowered to $80 from $95 at Wells Fargo » 06:45
02/23/22
02/23
06:45
02/23/22
06:45
EXAS

Exact Sciences

$73.59 /

-0.58 (-0.78%)

Wells Fargo analyst Dan…

Wells Fargo analyst Dan Leonard lowered the firm's price target on Exact Sciences to $80 from $95 and keeps an Equal Weight rating on the shares following quarterly results. The analyst believes the Street overestimates the growth prospects for its core products while meaningful contribution from several of its follow-on products is years away.

ShowHide Related Items >><<
EXAS Exact Sciences
$73.59 /

-0.58 (-0.78%)

EXAS Exact Sciences
$73.59 /

-0.58 (-0.78%)

02/23/22 Baird
Exact Sciences price target lowered to $100 from $116 at Baird
02/23/22 Citi
Exact Sciences price target lowered to $80 from $100 at Citi
11/03/21 BTIG
Exact Sciences price target lowered to $120 from $145 at BTIG
11/03/21 Craig-Hallum
Exact Sciences price target lowered to $133 from $144 at Craig-Hallum
EXAS Exact Sciences
$73.59 /

-0.58 (-0.78%)

EXAS Exact Sciences
$73.59 /

-0.58 (-0.78%)

Recommendations
Exact Sciences price target lowered to $100 from $116 at Baird » 06:41
02/23/22
02/23
06:41
02/23/22
06:41
EXAS

Exact Sciences

$73.59 /

-0.58 (-0.78%)

Baird analyst Catherine…

Baird analyst Catherine Ramsay Schulte lowered the firm's price target on Exact Sciences to $100 from $116 and keeps an Outperform rating on the shares. The analyst believes management's comments around expecting the year to be less back-end-loaded versus Street estimates reflects increased optimism in the near-term outlook and she thinks the company's own data releases could present meaningful catalysts for the stock in 2022.

ShowHide Related Items >><<
EXAS Exact Sciences
$73.59 /

-0.58 (-0.78%)

EXAS Exact Sciences
$73.59 /

-0.58 (-0.78%)

02/23/22 Citi
Exact Sciences price target lowered to $80 from $100 at Citi
11/03/21 BTIG
Exact Sciences price target lowered to $120 from $145 at BTIG
11/03/21 Craig-Hallum
Exact Sciences price target lowered to $133 from $144 at Craig-Hallum
11/03/21 Raymond James
Exact Sciences downgraded to Outperform from Strong Buy at Raymond James
EXAS Exact Sciences
$73.59 /

-0.58 (-0.78%)

EXAS Exact Sciences
$73.59 /

-0.58 (-0.78%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.